IR103: Phase II started

IMNR began a placebo-controlled, Remune-controlled, U.K. and Canadian Phase II trial in treatment-naïve patients. IR103 combines IMNR's HIV-1 immunogen with Amplivax, an immunostimulatory oligonucleot...